SCHEMBL3320664

SCHEMBL3320664

CCC1(CC)CC(N)c2ccc(C(F)(F)F)cc2O1

nearest known ligand 0.46

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 15/20 0.46
KDM1A O60341 4/20 0.41
RCOR1 Q9UKL0 2/20 0.41
PNMT P11086 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3320656 1.00 TRPV1 (0.46) TRPV1KDM1ARCOR1PNMT
SCHEMBL3327860 0.88 TRPV1 (0.46) TRPV1KDM1APNMT
SCHEMBL3327851 0.88 TRPV1 (0.46) TRPV1KDM1APNMT
SCHEMBL3320891 0.84 TRPV1 (0.46) TRPV1KDM1APNMT
SCHEMBL3317955 0.84 TRPV1 (0.46) TRPV1KDM1APNMT
SCHEMBL3322847 0.84 TRPV1 (0.46) TRPV1KDM1APNMT
Hydrochloric Acid SCHEMBL17708768 0.83 TRPV1 (0.45) TRPV1KDM1ARCOR1PNMT
SCHEMBL3321432 0.82 TRPV1 (0.44) TRPV1KDM1APNMT
SCHEMBL3319723 0.82 TRPV1 (0.42) TRPV1KDM1ARCOR1
SCHEMBL3321427 0.82 TRPV1 (0.44) TRPV1KDM1APNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609692-B2 TRPV1 antagonists ABBVIE INC. (US) 2013-12-17 US disclosed
US-8604053-B2 TRPV1 antagonists ABBVIE INC. (US) 2013-12-10 US disclosed
CN-102245587-A Trpv1 antagonists ABBOTT LAB 2011-11-16 CN disclosed
CN-102186836-A Trpv1 antagonists ABBOTT LAB 2011-09-14 CN disclosed
US-20100137360-A1 TRPV1 ANTAGONISTS ABBOTT LABORATORIES (US) 2010-06-03 US disclosed
US-20100120846-A1 TRPV1 ANTAGONISTS ABBOTT LABORATORIES (US) 2010-05-13 US disclosed
US-20090143423-A1 SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND ABBOTT GMBH & CO. KG (DE) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137360-A1 TRPV1 ANTAGONISTS TRPV1, TRPV3, TRPV2 TRPV1 1/4885KDM1A 3338/4885RCOR1 462/4885
US-20100120846-A1 TRPV1 ANTAGONISTS TRPV1, TRPV3, TRPV2 TRPV1 1/4885KDM1A 3414/4885RCOR1 451/4885
US-20090143423-A1 SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND U2SURP, UMPS, HNRNPUL1 TRPV1 4781/4885KDM1A 582/4885RCOR1 3230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.